IPCI Intellipharmaceutics International Inc.

0.85
-0.05  -5%
Previous Close 0.90
Open 0.88
Price To book 32.86
Market Cap 26433668
Shares 31,018,151
Volume 457,543
Short Ratio 9.25
Av. Daily Volume 371,274

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

PDUFA date September 25, 2017. Advisory Committee Meeting July 26, 2017 voted 22-1 against recommending approval. Note that the FDA is stayed from granting approval of Rexista until August 24, 2019 due to patent litigation.
Rexista
Pain relief

Latest News

  1. SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in IntelliPharmaCeutics International Inc. of Class Action Lawsuit and Upcoming Deadline - IPCI
  2. DEADLINE REMINDER: Lundin Law PC Announces Securities Class Action Lawsuit against IntelliPharmaCeutics International Inc. and Encourages Investors with Losses to Contact the Firm
  3. Intellipharmaceutics Announces Receipt of Nasdaq Notice
  4. IPCI SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Intellipharmaceutics International Inc. and a Lead Plaintiff Deadline of September 29, 2017
  5. 10-DAY DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against IntelliPharmaCeutics International Inc. and Encourages Investors with Losses to Contact the Firm
  6. ALERT: The Klein Law Firm Reminds Investors of Commencement of a Class Action Filed on Behalf of Intellipharmaceutics International Inc. Shareholders and a Lead Plaintiff Deadline of September 29, 2017 (IPCI)
  7. INVESTOR ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against IntelliPharmaCeutics International Inc. (IPCI) and Lead Plaintiff Deadline - September 29, 2017
  8. DEADLINE APPROACHING: Khang & Khang LLP Announces Securities Class Action Lawsuit against IntelliPharmaCeutics International Inc. and Encourages Investors with Losses to Contact the Firm
  9. LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 in IntelliPharmaCeutics International Inc. to Contact The Firm
  10. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders it Filed a Complaint to Recover Losses Suffered by Investors in Intellipharmaceutics International Inc. and Set a Lead Plaintiff Deadline of September 29, 2017 -- IPCI
  11. DEADLINE APPROACHING: Lundin Law PC Announces Securities Class Action Lawsuit against IntelliPharmaCeutics International Inc. and Encourages Investors with Losses to Contact the Firm
  12. IPCI EXPANDED CLASS PERIOD: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Intellipharmaceutics International Inc. and a Lead Plaintiff Deadline of September 29, 2017
  13. DEADLINE ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against IntelliPharmaCeutics International Inc. and Reminds Investors with Losses to Contact the Firm
  14. EXPANDED CLASS: Levi & Korsinsky, LLP Notifies Shareholders It Filed a Complaint to Recover Losses Suffered by Investors in Intellipharmaceutics International Inc. and Set a Lead Plaintiff Deadline of September 29, 2017 -- IPCI
  15. IPCI ALERT: Rosen Law Firm Reminds Intellipharmaceutics International Inc. Investors of Important Deadline in Class Action – IPCI
  16. SHAREHOLDER REMINDER: Lundin Law PC Announces Securities Class Action Lawsuit against IntelliPharmaCeutics International Inc. and Reminds Investors with Losses to Contact the Firm
  17. IPCI EXPANDED CLASS: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Intellipharmaceutics International Inc. and a Lead Plaintiff Deadline of September 29, 2017
  18. SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in IntelliPharmaCeutics International Inc. of Class Action Lawsuit and Upcoming Deadline - IPC